Bio Equity Europe (Agennix) - May 15, 2012 - Anticipated top-line data of P3 FORTIS-M trial for NSCLC in Jul/Aug 2012; Anticipated composition of matter/production patent expiry in US in Q4 2013; Anticipated cancer use patent expiry in US in 2025; Anticipated composition of matter/production patent expiry in EU in Q4 2013; Anticipated cancer use patent expiry in EU in 2023
Anticipated P3 top line data • Anticipated patent expiry • Non Small Cell Lung Cancer
|
|
talactoferrin
-- -- --
FORTIS-M phase 3 trial in 3rd line NSCLC top-line data expected in July/August 2012
Composition of matter/production patent expiry in US in Q4 2013
Cancer use patent expiry in US 2025
Composition of matter/production patent expiry in EU in Q4 2013
Cancer use patent expiry in EU 2023
-- -- --
|